Despite the recognition that EGFR overexpression in breast tumors may affect disease progression [8], the responses of anti-EGFR therapies in breast cancer are not fully satisfactory [9], and the reasons for this clinical variability are not fully understood. This evidence concerns the gene EGFR and breast cancer.